Logo image of ISO

ISOPLEXIS CORP (ISO) Stock Fundamental Analysis

NASDAQ:ISO - Nasdaq - US4650051067 - Common Stock - Currency: USD

0.7616  +0.02 (+2.78%)

Fundamental Rating

2

ISO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 54 industry peers in the Life Sciences Tools & Services industry. ISO has a bad profitability rating. Also its financial health evaluation is rather negative. ISO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ISO had negative earnings in the past year.
ISO had a negative operating cash flow in the past year.
ISO Yearly Net Income VS EBIT VS OCF VS FCFISO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for ISO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISO Yearly ROA, ROE, ROICISO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

ISO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISO Yearly Profit, Operating, Gross MarginsISO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

ISO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ISO has more shares outstanding
Compared to 1 year ago, ISO has a worse debt to assets ratio.
ISO Yearly Shares OutstandingISO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
ISO Yearly Total Debt VS Total AssetsISO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

ISO has an Altman-Z score of -5.00. This is a bad value and indicates that ISO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ISO (-5.00) is worse than 90.63% of its industry peers.
ISO has a Debt/Equity ratio of 1.12. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ISO (1.12) is worse than 82.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF N/A
Altman-Z -5
ROIC/WACCN/A
WACC12.77%
ISO Yearly LT Debt VS Equity VS FCFISO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

ISO has a Current Ratio of 4.06. This indicates that ISO is financially healthy and has no problem in meeting its short term obligations.
ISO has a Current ratio of 4.06. This is comparable to the rest of the industry: ISO outperforms 53.13% of its industry peers.
ISO has a Quick Ratio of 2.50. This indicates that ISO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.50, ISO is in line with its industry, outperforming 40.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.06
Quick Ratio 2.5
ISO Yearly Current Assets VS Current LiabilitesISO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ISO have decreased strongly by -14.08% in the last year.
The Revenue has decreased by -2.88% in the past year.
The Revenue has been growing by 30.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
Revenue 1Y (TTM)-2.88%
Revenue growth 3Y30.71%
Revenue growth 5YN/A
Sales Q2Q%-39.35%

3.2 Future

The Earnings Per Share is expected to grow by 24.09% on average over the next years. This is a very strong growth
ISO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.04% yearly.
EPS Next Y48%
EPS Next 2Y24.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.37%
Revenue Next 2Y56.88%
Revenue Next 3Y55.04%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ISO Yearly Revenue VS EstimatesISO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ISO Yearly EPS VS EstimatesISO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ISO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISO Price Earnings VS Forward Price EarningsISO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISO Per share dataISO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ISO's earnings are expected to grow with 24.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.09%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ISO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISOPLEXIS CORP

NASDAQ:ISO (3/20/2023, 8:17:18 PM)

0.7616

+0.02 (+2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-02 2023-03-02/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.35%
Ins Owner Change0%
Market Cap30.21M
Analysts46.67
Price Target1.63 (114.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-61.16%
Min EPS beat(2)-113.25%
Max EPS beat(2)-9.06%
EPS beat(4)0
Avg EPS beat(4)-41.24%
Min EPS beat(4)-113.25%
Max EPS beat(4)-9.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.05%
Min Revenue beat(2)-42%
Max Revenue beat(2)-4.11%
Revenue beat(4)1
Avg Revenue beat(4)-15.53%
Min Revenue beat(4)-42%
Max Revenue beat(4)9.55%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-2.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.55%
Revenue NY rev (1m)5.36%
Revenue NY rev (3m)5.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.8
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.42
BVpS1.04
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 221.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.06
Quick Ratio 2.5
Altman-Z -5
F-Score2
WACC12.77%
ROIC/WACCN/A
Cap/Depr(3y)510.76%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.42%
EPS Next Y48%
EPS Next 2Y24.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.88%
Revenue growth 3Y30.71%
Revenue growth 5YN/A
Sales Q2Q%-39.35%
Revenue Next Year49.37%
Revenue Next 2Y56.88%
Revenue Next 3Y55.04%
Revenue Next 5YN/A
EBIT growth 1Y-27.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.89%
EBIT Next 3Y21.07%
EBIT Next 5YN/A
FCF growth 1Y5.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.72%
OCF growth 3YN/A
OCF growth 5YN/A